As advanced therapies drive increasing market consolidation, the US giant Agilent Technologies has acquired the Canadian contract development and manufacturing organization (CDMO) BIOVECTRA for $925 million.
Contract development and manufacturing organizations (CDMOs) perform vital services for the biopharmaceutical industry – a role that is growing as cell and gene therapies gain momentum. Here are five of the top CDMOs bringing advanced therapies toward...
Andelyn Biosciences, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been chosen by UMass Chan Medical School to manufacture clinical-grade AAV9-CSA vector using its suspension AAV Curator Platform...
As Saudi Arabia seeks to make its healthcare system more cost-efficient, the private equity firm TVM Capital Healthcare is betting $35 million on the Saudi Arabia-based bio-generics provider Boston Oncology Arabia.
Yesterday (June 24) Novo Nordisk unveiled plans to invest $4.1 billion (approximately €3.8 billion) in a new manufacturing facility in Clayton, North Carolina.
Thermo Fisher’s new state-of-the-art ultra-cold facility in Bleiswijk, Netherlands, aims to accelerate advanced therapies development by offering a comprehensive range of cold and ultra-cold services.
Director of cell and gene therapy R&D at Lonza, this week's inspiring female is Inbar who we spoke to about her passion for discovering the future and mentor support sparked her early interest in biology and informed her journey of resiliency.
EXO Biologics, a clinical-stage biotech specializing in exosome-based therapies, recently announced the successful raising of €16 million in Series A funding.
Daniel Spurgin, director of strategic partnerships at ReciBioPharm, unveiled the company's BIO 2024 plans and how the CDMO is set to flourish as more viral and nucleic acid therapeutics move to the clinic in the next two years.
Before the industry is set to arrive in San Diego for Bio International 2024, we spoke with Dr. Harald Oberegger, global head business development at Novartis Contract Manufacturing. At the event, the company will be showcasing its cutting-edge technologies,...
In a recent interview, Hayley Crowe, head of Ecolab's global life sciences business, shed light on Purolite's latest developments and its significant contributions to the biopharmaceutical industry.
Torbay Pharmaceuticals is a sterile injectable contract manufacturer and licence holder based in Devon, UK. We spoke with CEO Emma Rooth about the company's heritage and how it is striving to support the U.S. market.
What is ADC specialist Piramal Pharma planning for the upcoming CPHI North America conference? We sat down with chief commercial officer Stuart Needleman to find out what's on the company's agenda.
Ahead of CPHI North America, we caught up with Lisa Stiles, director, business development at Selkirk Pharma, an exhibitor at the event, to find out how the CMO is navigating regulatory changes, challenges and more.
Patrick Thiaville is chief scientific officer of Exothera Nucleic Acids, a viral vector CDMO (contract manufacturing and development organization) using standard and innovative bioproduction platforms to rapidly deliver affordable viral vector-based vaccines...
OSP was delighted to talk to Vetter’s Carsten Press, a senior leader of the global sales organization, and business development among many operational functions.
Johnson & Johnson’s Janssen Supply Group is to be the first tenant in Fujifilm Diosynth Biotechnologies’ $2 billion cell culture manufacturing facility, which is planned to open in Holly Springs, North Carolina, in 2025.
The Australian biotech GPN Vaccines has expanded a partnership with compatriot contract development and manufacturing organization (CDMO) BioCina to scale up the manufacture of its lead candidate vaccine against pneumococcal diseases such as pneumonia,...
Sharp, a commercial pharma packaging and clinical trial supply services firm, has acquired Berkshire Sterile Manufacturing (BSM), a Massachusetts-based fill finish contract development and manufacturing organization (CDMO).
Sigma Mostafa is the chief scientific officer of KBI Biopharma, a development and contract manufacturing organization serving the biopharmaceutical industry.
Biovian, a leading contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, has announced a major investment of over €50 million to expand its manufacturing facility in Turku, Finland.
UK contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions, has completed the build of its new development and GMP manufacturing headquarters in Nottingham, UK.
Last month, CDMO giant Samsung Biologics revealed it was planning to have its fifth plant operational by April 2025, five months earlier than previously anticipated.
Saudi Arabia’s Public Investment Fund (PIF) has launched a new commercial-scale contract development and manufacturing organization (CDMO) called Lifera.
As the global contract development and manufacturing organization (CDMO) market continues to grow, we caught up with Federico Pollano, SVP business development at Rentschler Biopharma, at Bio International 2023, to discuss the company's ongoing growth...
Samsung Biologics’ upcoming fifth plant will be operational by April 2025, five months earlier than previously expected, the biotech company revealed at BIO International Convention on Monday 5.
A ‘significant shift’ is under way in global outsourcing strategies: with the sector moving away from phase-appropriate development in favor of a more forward-looking model – with experts advising starting the search for an outsourcing partner as early...
Bavarian Nordic has entered into an agreement with Grand River Aseptic Manufacturing (GRAM), a US based contract manufacturer, for fill and finish of the Jynneos smallpox/monkeypox vaccine in the country.
Bionova Scientific, a US biologics CDMO, is to be acquired by the US arm of Asahi Kasei Medical, part of the Asahi Kasei Group, owned by Tokyo based Asahi Kasei Corporation.
GC Corp, the holding company for GC group in South Korea, has moved to acquire 100% of the shares of BioCentriq, Inc, a US CDMO that designs and develops scalable cell and gene technologies (CGTs).
Novartis continues down the third-party manufacturing route, as it secures an agreement with Carisma Therapeutics, a firm developing a cell therapy platform focused on engineered macrophage-based therapeutics.
During CPhI Worldwide, leaders from two organizations will outline how CM is taking off, potential benefits, and how to clear common obstacles to adoption.
An expert speaking during the industry event offers insight and perspective on the flurry of CDMO deal-making in recent months, and what might lie ahead.
